Oculis (NASDAQ:OCS) Shares Gap Up – Still a Buy?

Oculis Holding AG (NASDAQ:OCS) shares gapped up prior to trading on Friday . The stock had previously closed at $16.93, but opened at $17.64. Oculis shares last traded at $17.45, with a volume of 51,109 shares.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Oculis in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Oculis has an average rating of “Buy” and a consensus price target of $29.20.

Oculis Price Performance

The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $16.28 and a two-hundred day moving average of $13.68. The company has a market cap of $708.82 million, a PE ratio of -9.07 and a beta of -0.34.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.